Table 1 Clinical features and details of patients receiving intravenous PMB
Characteristic | Mean ± SD, or n (%) |
|---|---|
Age (year) | 55.91 ± 17.14 |
Male (%) | 79 (79) |
ICU admission, n (%) | 98 (98) |
Mechanical ventilation, n (%) | 49 (49) |
Chronic medical conditions, n (%) | |
 Heart disease | 14 (14) |
 Hypertension | 44 (44) |
 Stroke | 19 (19) |
 Cancer | 6 (6) |
 Diabetes mellitus | 15 (15) |
 Chronic obstructive pulmonary disease | 1 (1) |
Renal insufficiency, n (%) | 27 (27) |
Septic shock, n (%) | 39 (39) |
SOFA score, mean ± SD | 7.76 ± 4.30 |
APACHE II, mean ± SD | 17.61 ± 7.59 |
ICU stay before intravenous PMB, days, median (IQR) | 8 (3, 14) |
MODS, n (%) | 60 (60) |
PCT, ng/ml, median (IQR) | 3.89 (1.08, 11.43) |
Bacterial, n (%) | |
 AB | 33 (33) |
 KP | 48 (48) |
 PA | 16 (16) |
 Other | 9 (9) |
 Unknown | 15 (15) |
Infection sites, n (%) | |
 BSI | 40 (40) |
 Pulmonary infection | 64 (64) |
 Intraperitoneal infection | 9 (9) |
 Incision infection | 6 (6) |
 Others | 18 (18) |
Concomitant antibiotic therapy | |
 PMB + Carbapenem | 30 (30) |
 PMB + Carbapenem + Tigecycline | 26 (26) |
 PMB + Tigecycline | 11 (11) |
 PMB + Cephalosporin | 9 (9) |
 PMB + Carbapenem + Cephalosporin | 8 (8) |
 Others | 16 (16) |
Daily dose of PMB, mg/day, n (%) | |
 100 | 53 (53) |
 150 | 17 (17) |
 200 | 30 (30) |